We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ATOS Atossa Therapeutics Inc

-0.02 (-2.00%)
01 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Atossa Therapeutics Inc ATOS NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.02 -2.00% 0.98 11:59:45
Open Price Low Price High Price Close Price Previous Close
1.00 0.966 1.02 0.977 1.00
more quote information »

Recent News

Date Time Source Heading
23/2/202400:30GLOBEAtossa Therapeutics Announces First Patient Dosing of..
08/2/202400:30GLOBEAtossa Therapeutics Announces Full Enrollment..
10/1/202400:30GLOBEAtossa Therapeutics Issues Letter to Shareholders
05/12/202300:30GLOBEAtossa Therapeutics Announces the Appointment of Arezoo..
21/11/202300:30GLOBEAtossa Therapeutics Announces Full Enrollment of Phase 2..
16/11/202309:03EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
16/11/202308:15EDGAR2Form 3 - Initial statement of beneficial ownership of..
16/11/202308:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202301:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202301:00EDGAR2Form 8-K - Current report
14/11/202301:00GLOBEAtossa Therapeutics Announces Third Quarter 2023 Financial..
10/11/202301:00EDGAR2Form 8-K - Current report
10/11/202301:00GLOBEAtossa Therapeutics Appoints Financial Executive Jonathan..
31/10/202304:00PRNUSQuantum Leap Healthcare Collaborative Initiates Landmark..
17/10/202307:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
11/10/202323:30PRNUSFast-food consumption by adolescent girls may sow the seeds..
07/10/202307:00EDGAR2Form 8-K - Current report
29/9/202306:28EDGAR2Form 8-K - Current report
18/9/202322:30GLOBEAtossa to Present at Cantor Fitzgerald Global Healthcare..
14/8/202322:35EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202322:30EDGAR2Form 8-K - Current report
14/8/202322:30GLOBEAtossa Therapeutics Announces Second Quarter 2023 Financial..
08/8/202323:00GLOBEAtossa Therapeutics to Provide Business Update and Report..
20/7/202323:15GLOBEAtossa Therapeutics Receives Approval from Health Canada to..
14/7/202306:20EDGAR2Form 8-K - Current report
14/7/202306:15GLOBEAtossa Therapeutics Regains Compliance with Nasdaq Minimum..
10/7/202323:15GLOBEAtossa Therapeutics Provides Enrollment Update for Ongoing..
06/7/202323:15GLOBEAtossa Therapeutics Announces Sponsored Research Agreement..
28/6/202323:15GLOBEAtossa Therapeutics and Quantum Leap Healthcare Provide..
28/6/202323:01EDGAR2Form 8-K - Current report
27/6/202323:15GLOBEAtossa Therapeutics Announces $10M Stock Repurchase Program
23/6/202306:15GLOBEAtossa Therapeutics Announces Sponsorship of Are You Dense..
22/6/202300:13GLOBEAtossa Therapeutics Granted Additional Patent Protection for..
14/6/202323:15GLOBEAtossa to Participate in Fireside Chat at Healthcare Virtual..
12/6/202323:15GLOBEAtossa Completes Enrollment of Pharmacokinetic Run-In Cohort..
01/6/202323:10GLOBEAtossa Appoints Life Sciences Financial and Operations..
23/5/202321:00GLOBESocietal CDMO Enters Agreement With Atossa Therapeutics to..
15/5/202323:10GLOBEAtossa Therapeutics Announces First Quarter 2023 Financial..
11/5/202323:00PRNUSPhysician-Scientist Dr. Steven Quay Provides Recommendations..
09/5/202323:15GLOBEAtossa to Present a Trial in Progress Poster on its..
27/4/202323:15GLOBEAtossa Therapeutics to Participate in Tribe Public’s Webinar..
23/3/202307:05GLOBEAtossa Therapeutics Announces Year-End 2022 Financial..
22/3/202304:19PRNUSAtossa Therapeutics and Quantum Leap Healthcare Announce New..
22/3/202300:15GLOBEAtossa Therapeutics and Quantum Leap Healthcare Announce New..
16/3/202300:25GLOBEAtossa to Present at the Sidoti Small-Cap Virtual Conference

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |